AriBio TeloAct Acquires Hair Loss Functional Cosmetics Permission from the Ministry of Food and Drug Safety...12 Overseas Countries Prepare Patents
Oct 01, 2025
Aribio (CEO Jeong Jae-joon) announced on the 1st that the solution 'Telloact', which is applied with new technology to alleviate hair loss symptoms, has been approved by the Ministry of Food and Drug Safety (MFDS) for hair loss functional cosmetics. With this permission, Aribio will expand domestic demand and advance into overseas markets through distribution of hospitals and clinics in Korea in response to consumer demands for fundamental solutions to hair loss.
Aribio succeeded in developing a patented raw material that induces hair follicle stem cell activation through industry-academia research with the university (Professor Shin Deuk-yong's team at Korea University). After five years of long-term research, the research team scientifically identified that the restoration of scalp and hair follicle function is the essence of hair loss resolution, and proved its efficacy and safety through clinical trials. Six domestic patent registrations have been completed, and international patent applications will be filed within this year in 12 countries, including the United States, Europe, China, and Japan.
Teloact was created based on the study of the enzyme 'Telomerase', which is the key to cell aging and longevity. Telomerase restores shorter telomeres during cell division to maintain cell vitality and regenerative capacity. In particular, hair follicle stem cells are highly dependent on these mechanisms, and when telomerase is activated, resting hair follicles are converted to growth phase, promoting new hair production.
The Ari Bio research team independently developed a patent raw material ultra-fine technology to maximize the mechanism of telomerase action. The patented raw material is designed to be smaller than the cell gap and delivers the active ingredients deep into the scalp. As a result, it not only alleviates hair loss, but also improves scalp health and hair quality at the same time.
The TeloAct clinical trial was conducted for 24 weeks with 43 human-applied trials. As a result, the hair density (total number of hairs) increased significantly compared to the control group, and the skin stimulation test was also judged non-stimulating, satisfying the effectiveness and safety expected by consumers at the same time, the researchers said. In the clinical process, ▲improvement of scalp blood flow without side effects ▲increase of scalp elasticity ▲preventability of keratin and oxidative stress were confirmed from various angles. The improvement effect was evident from approximately 4 or 7 weeks.
Seo Bo-seung, Ari Bio Bio"TelloAct is an innovative hair loss symptom relief product developed by combining independently developed raw materials and ultra-fine delivery technology beyond the existing limits. We will first launch functional cosmetics in domestic and international markets, and then begin research to expand exports and develop them as hair loss drugs," said the head of the Medical Research Institute.
Meanwhile, Aribio is developing new drugs for next-generation dementia with six pipelines, including AR1001 and AR1002 to AR1006, which are undergoing phase 3 global clinical trials. At the same time, long-term research and development (R&D) and investment have recently made clear results in the field of biomedical devices. Following the launch of the brain stimulation cognitive function device 'Herzion', it succeeded in exporting a self-developed hyaluronic acid filler worth KRW 34 billion. With the approval of the Ministry of Food and Drug Safety, we have secured additional key growth engines to expand sales in domestic and international markets.
Aribio is seeking to merge with Sorux, a KOSDAQ listed company. The planned merger date is January 20, 2026.
Aribio succeeded in developing a patented raw material that induces hair follicle stem cell activation through industry-academia research with the university (Professor Shin Deuk-yong's team at Korea University). After five years of long-term research, the research team scientifically identified that the restoration of scalp and hair follicle function is the essence of hair loss resolution, and proved its efficacy and safety through clinical trials. Six domestic patent registrations have been completed, and international patent applications will be filed within this year in 12 countries, including the United States, Europe, China, and Japan.
Teloact was created based on the study of the enzyme 'Telomerase', which is the key to cell aging and longevity. Telomerase restores shorter telomeres during cell division to maintain cell vitality and regenerative capacity. In particular, hair follicle stem cells are highly dependent on these mechanisms, and when telomerase is activated, resting hair follicles are converted to growth phase, promoting new hair production.
The Ari Bio research team independently developed a patent raw material ultra-fine technology to maximize the mechanism of telomerase action. The patented raw material is designed to be smaller than the cell gap and delivers the active ingredients deep into the scalp. As a result, it not only alleviates hair loss, but also improves scalp health and hair quality at the same time.
The TeloAct clinical trial was conducted for 24 weeks with 43 human-applied trials. As a result, the hair density (total number of hairs) increased significantly compared to the control group, and the skin stimulation test was also judged non-stimulating, satisfying the effectiveness and safety expected by consumers at the same time, the researchers said. In the clinical process, ▲improvement of scalp blood flow without side effects ▲increase of scalp elasticity ▲preventability of keratin and oxidative stress were confirmed from various angles. The improvement effect was evident from approximately 4 or 7 weeks.
Seo Bo-seung, Ari Bio Bio"TelloAct is an innovative hair loss symptom relief product developed by combining independently developed raw materials and ultra-fine delivery technology beyond the existing limits. We will first launch functional cosmetics in domestic and international markets, and then begin research to expand exports and develop them as hair loss drugs," said the head of the Medical Research Institute.
Meanwhile, Aribio is developing new drugs for next-generation dementia with six pipelines, including AR1001 and AR1002 to AR1006, which are undergoing phase 3 global clinical trials. At the same time, long-term research and development (R&D) and investment have recently made clear results in the field of biomedical devices. Following the launch of the brain stimulation cognitive function device 'Herzion', it succeeded in exporting a self-developed hyaluronic acid filler worth KRW 34 billion. With the approval of the Ministry of Food and Drug Safety, we have secured additional key growth engines to expand sales in domestic and international markets.
Aribio is seeking to merge with Sorux, a KOSDAQ listed company. The planned merger date is January 20, 2026.
|
This article was translated by Naver AI translator.
